Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘BRAF V600’

ESMO24 Preview 2 – Hurdles and Prospects

The Basílica i Temple Expiatori de la Sagrada Família in Barcelona

I’ve always found Gaudi’s gothic cathedral in Barcelona beautiful and inspiring inside despite its ugly gothic facade.

The way the light and space combine to produce a sense of awe and wonder is a nice way to forget the trials and tribulations in the outside world.

In our latest ESMO Preview we look at a particular niche, which has seen many changes in its landscape over the last few years, including some ugly data as well as areas giving greater hope for investigators and patients alike.

This year looks like continuing both trends in equal measure…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Can C4 take protein degraders to new heights?

Protein degraders and molecular glue degraders have certainly been a very hot topic of late.  One company we have been following for a while in this niche is Watertown, MA based C4 Therapeutics, who have a growing pipeline of early stage agents in development.

Setting sights on new horizons

Last year we talked with them about various strategic topics such as what makes a great target for a protein degrader and other stories.

This time around it’s time to move the discussion along by looking forward to the future and explore why the science behind their pipeline will set them up for future success in the clinic.

Obviously this isn’t guaranteed in oncology R&D and degraders are certainly not the easiest approach technically, yet they do offer a lot of potential.

In our latest expert interview we talk in detail about the C4 degrader pipeline and how they have gone about optimising their molecules for clinical performance…

BSB subscribers can read up on our ongoing commentary and analysis from the JPM conference – you can either log-in or click to access the back story behind the latest innovations.

This content is restricted to subscribers

The value of BRAF targeted cancer therapies in lung and colorectal cancer

It’s time for the August mailbag where we answer questions about cancer research and R&D from subscribers.

After the recent queries about immuno-oncology, it’s time to focus a little on targeted therapies again. Neither chemotherapies nor targeted therapies are going to go away – they are still the bedrock of many treatment approaches in the clinic today. Sadly though, much of the new data for the latter trials were easily swamped by the sheer tsunami of immunotherapy data in Philadelphia (AACR) and Chicago (ASCO).

One important area that we have been discussing on both blogs for some time is the value of well designed basket trials.  It’s time to revisit this concept in the light of new data relating to the BRAF V600 mutation outside of metastatic melanoma.

To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

error: Content is protected !!